Jun. 12, 2012, 8:19 AM(GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial £146M ($227M) to acquire eczema drug Toctino from Swiss biotech Basilea (BPMUF.PK). GSK will pay another £50M if Toctino passes its Phase III trial and receives FDA approval, and royalties on U.S. sales starting three years after launch. | Comment!
BPMUF vs. ETF Alternatives
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to... More
Other News & PR